In China, the pharmaceutical sales of sample hospitals have an increase trend due to the population growth, awareness of the importance of health care, and increased aging population. Among all drug sales, the share of anti-infectives in recent years has always been at the top of the list. Therefore, CRI predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.

According to the CRI’s market research, the sales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019. The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019. The reason for the decline is due to COVID-19. The CAGR of the total sales from 2016 to 2020 is 6.24%. Therefore, CRI analyzes that as the epidemic situation improves, the overall sales in China are expected to have a recovery growth in 2021-2025. In addition, after the implementation of the “4 + 7” policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.

Topics Covered:
-The impact of COVID-19 on China’s Cefoperazone Sodium and Sulbactam Sodium market
– Sales value and volume of China’s Cefoperazone Sodium and Sulbactam Sodium 2016-2020
– Competitive landscape of China’s Cefoperazone Sodium and Sulbactam Sodium market
– Prices of Cefoperazone Sodium and Sulbactam Sodium in China
– Prices of Cefoperazone Sodium and Sulbactam Sodium in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Cefoperazone Sodium and Sulbactam Sodium market
– Prospect of China’s Cefoperazone Sodium and Sulbactam Sodium market from 2021 to 2025

The post Investigation Report on Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025 first appeared on CRI Report.

CRI’s market research shows that sales of Atorvastatin began to decline in 2019, and the CAGR from 2016 to 2020 is approximately -0.92%. The main reason is that retail pharmacies have taken more Atorvastatin sales after 2019, which causes the sales decline in sample hospitals. Since thfe research data is based on medications used in sample hospitals, the result cannot indicate that Atorvastatin is unpopular in the Chinese market. The sales revenue in 2020 is around CNY0.82 billion, though it dropped about 58% compared to 2019 due to the lost sales and COVID-19 epidemic.

CRI concludes that the Chinese Atorvastatin market will still have a growth trend in the short run. The sales of Atorvastatin will recover due to the improvement of the epidemic situation. In addition, sales will increase as the market expands. The expansion of the market is based on the increase of consumers. With the implementation of the “4+7” policy (a plan for centralized purchasing), the price of Atorvastatin should continue to fall. As a result, except for the patients with high cholesterol, patients with other indications, such as patients with cardiovascular-related diseases may become the target of the drug.

Topics Covered:
-The impact of COVID-19 on China’s atorvastatin market
– Sales value and volume of China’s atorvastatin 2016-2020
– Competitive landscape of China’s atorvastatin market
– Prices of atorvastatin in China
– Prices of atorvastatin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s atorvastatin market
– Prospect of China’s atorvastatin market from 2021 to 2025

The post Investigation Report on Chinese Atorvastatin Market 2021-2025 first appeared on CRI Report.

In the Chinese market, with the prevalence of chronic diseases, the improvement of the medical system, and the intensification of aging in some regions, the number of operations has increased. Moreover, due to the therapeutic advantages of Sevoflurane, it dominates the anesthesia market. Therefore, CRI predicts that the sales of Sevoflurane will increase in the future.

According to CRI’s market research, the sales revenue of Sevoflurane in the Chinese market has increased from 2017 to 2019, and reached CNY729.39 million in 2019. The CAGR for Sevoflurane from 2016 to 2019 is about 2.41%. In 2020, due to the COVID-19 epidemic, the number of surgeries decreased. Thus, the sales of Sevoflurane decreased accordingly. However, CRI analyzes that as the epidemic has improved, the sales of Sevoflurane in the Chinese market will have a recovery growth in 2021-2025.

Topics Covered:
-The impact of COVID-19 on China’s sevoflurane market
– Sales value and volume of China’s sevoflurane 2016-2020
– Competitive landscape of China’s sevoflurane market
– Prices of sevoflurane in China
– Prices of sevoflurane in China by regions and manufacturers
– Analysis on factors affecting the development of China’s sevoflurane market
– Prospect of China’s sevoflurane market from 2021 to 2025

The post Investigation Report on Chinese Sevoflurane Market, 2021-2025 first appeared on CRI Report.

According to CRI market research, after Pembrolizumab entered the Chinese market, its sales revenue has increased several times. The revenue in 2020 reaches approximately CNY 294.75 million, and the CAGR is 284.67% from 2018 to 2020. Thus, CRI analyzes that the market size of Pembrolizumab will expand in the future due to the increased numbers of approved indications.

In addition, PD-1-type drug is not very common in the Chinese market, so Merck Sharp & Dohme Corp, as the only supplier of Pembrolizumab in China, did not face any threat in the past. However, in December 2018, a PD-1 drug produced by Junshi Biosciences has been successfully approved for marketing. Therefore, CRI predicts that from 2021 to 2025, the price of Pembrolizumab in China may be lowered, but the market will continue to expand due to Pembrolizumab’s effectiveness and unsaturated demand.

Topics Covered:
-The impact of COVID-19 on China’s pembrolizumab market
– Sales value and volume of China’s pembrolizumab 2016-2020
– Competitive landscape of China’s pembrolizumab market
– Prices of pembrolizumab in China
– Prices of pembrolizumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s pembrolizumab market
– Prospect of China’s pembrolizumab market from 2021 to 2025

The post Investigation Report on Chinese Pembrolizumab Market, 2021-2025 first appeared on CRI Report.

In the Chinese pharmaceutical market, narcotic analgesics have grown very fast in recent years, mainly due to massive surgeries in China. According to Chinese statistics, there will be more than 50 million operations in 2019, and the amount of surgeries is increasing year by year. In narcotic analgesics, Dezocine accounts for up to 60% of the market share.

According to CRI’s market research, the sales of Dezocine had a growth trend from 2016 to 2019. The revenue in 2020 was approximately CNY2.06 billion, though it decreased by 6.18% compared to 2019 due to the COVID-19 epidemic. The CAGR of sales from 2016 to 2020 is 8.77%. Therefore, CRI analyzes that, with the improvement of the epidemic situation, the sales of Dezocine in China are expected to have a recovery growth in 2021-2025.

Topics Covered:
-The impact of COVID-19 on China’s dezocine market
– Sales value and volume of China’s dezocine 2016-2020
– Competitive landscape of China’s dezocine market
– Prices of dezocine in China
– Prices of dezocine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s dezocine market
– Prospect of China’s dezocine market from 2021 to 2025

The post Investigation Report on Chinese Dezocine Market, 2021-2025 first appeared on CRI Report.

In the Chinese pharmaceutical market, Budesonide mainly has three dosage forms, including inhalation suspension, gas (powder) aerosol, and nasal spray. The most common one is Budesonide inhalation suspension, which was first developed and produced by AstraZeneca. In 2001, Budesonide entered the Chinese market. By 2020, the main manufacturers of Budesonide in China are AstraZeneca, Chia Tai Tianqing, Synmosa Biopharma, and Lunan.

According to CRI market research, the sales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%. However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 epidemic. The sales revenue in 2020 was approximately CNY1.1 billion. With the improvement of the epidemic situation, CRI predicts that the sales of Budesonide in China will have a recovery growth in the short run.

In recent years, the respiratory sector in the Chinese pharmaceutical market has a growth trend, mainly due to the heavy burden of asthma patients, the high smoking rate, and the deepening of aging. Thus, CRI analyzes that in addition to the recovery growth, the sales of Budesonide will increase in 2021-2025 as the market expands.

Topics Covered:
-The impact of COVID-19 on China’s budesonide market
– Sales value and volume of China’s budesonide 2016-2020
– Competitive landscape of China’s budesonide market
– Prices of budesonide in China
– Prices of budesonide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s budesonide market
– Prospect of China’s budesonide market from 2021 to 2025

The post Investigation Report on Chinese Budesonide Market 2021-2025 first appeared on CRI Report.

According to CRI’s research, the sales of Bevacizumab in the Chinese market keeps increasing since 2016. Although the growth rate has slowed down in the past two years, the CAGR from 2016 to 2020 is still as high as about 32%.

CRI analyzes that the sales of Bevacizumab in China will continue to grow due to market expansion. After the medical insurance negotiations in 2017, the price of AVASTIN decreased from CNY5176 to CNY1998. In 2020, the price was adjusted to CNY1500 due to the emergence of biosimilar drugs. Until June 2020, six companies have submitted go-public applications for Bevacizumab. Therefore, as more biosimilar drugs appear in the market, the price of Bevacizumab will probably drop again in the future, which will further open up the market.

Topics Covered:
-The impact of COVID-19 on China’s bevacizumab market
– Sales value and volume of China’s bevacizumab 2016-2020
– Competitive landscape of China’s bevacizumab market
– Prices of bevacizumab in China
– Prices of bevacizumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s bevacizumab market
– Prospect of China’s bevacizumab market from 2021 to 2025

The post Investigation Report on Chinese Bevacizumab Market 2021-2025 first appeared on CRI Report.

According to CRI, the incidence and case fatality rate of respiratory diseases in China are high in recent years. Following cardiovascular and cerebrovascular diseases and cancers, respiratory diseases rank third among the chronic diseases that cause deaths in China. Therefore, developing drugs for the treatment of respiratory diseases has become an important part of drug research.

In the case of respiratory infections (respiratory diseases such as chronic bronchitis), a large amount of sputum is produced, which requires the application of expectorants. Respiratory mucus regulators are the main expectorants.

After years of development, third-generation expectorant ambroxol has become the most common drug in the clinical treatment of respiratory diseases. The chemical constituent of ambroxol is ambroxol hydrochloride, an active metabolite of Bromhexine. In 1981, ambroxol (trade name: Mucosolvan) developed by German company Boehringer Ingelheim was launched.

Compared with the first and second generations of expectorants, ambroxol excels in dissolving mucus. In 1994, Boehringer Ingelheim’s ambroxol entered China. Afterwards, the generic drugs by Chinese companies also came onto the market.

According to CRI’s market research, ambroxol has been growing rapidly since it entered China. From 2005 to 2014, its annual sales value increased from less than CNY 200 million to CNY 1.26 billion, representing a CAGR of 20.9%. From 2015 to2020, the sales revenue of ambroxol declined in China. By sales value, Boehringer Ingelheim takes up a market share of about 47.75% in the year of2020.

The rest market share is captured by Chinese companies, among which the top market players are Changzhou Siyao Pharmaceuticals Co., Ltd., Shenyang Xinma Pharmaceutical Co., Ltd., TIPR Pharmaceutical Responsible Co., Ltd. and. Cisen Pharmaceutical Co., Ltd. Ambroxol is sold in China in the dosage forms of injections, solutions, syrups, granules, tablets and capsules mainly. Injections dominate the market.

Due to the outbreak of COVID-19 in 2020, the ability of Chinese hospitals to receive patients has declined. The decrease in the number of people seeking medical care makes China’s sales and sales of ambroxol show a downward trend in 2020. The sales of amboxol in China has dropped by 34% in 2020, compared to 2019.

According to CRI, in 2021-2025, the Chinese ambroxol market will gradually recover. It is estimated that the sales of ambroxol in China will reach CNY924 million in 2025, and the CAGR will reach 10% in 2021-2025.

Topics Covered:
-The impact of COVID-19 on China’s ambroxol market
– Situation of respiratory diseases in China
– Sales value and volume of China’s ambroxol 2016-2020
– Competitive landscape of China’s ambroxol market
– Prices of ambroxol in China
– Prices of ambroxol in China by regions and manufacturers
– Analysis on factors affecting the development of China’s ambroxol market
– Prospect of China’s ambroxol market from 2021 to 2025

The post Investigation Report on China’s Ambroxol Market, 2021-2025 first appeared on CRI Report.

The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China’s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.

The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger sales market share with lower prices advantage. In 2020, the sales amount of Shanghai Zhongxi Pharmaceutical is as high as CNY 233 million, and the market share is 68.05%.

Hydroxychloroquine has been tried out in search for its effectiveness of prevention and treatment for coronavirus diseases in the first half of 2020. In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases. The preliminary results of clinical studies in China and France showed that hydroxychloroquine is effective and safe. On March 28, 2020, the U.S. Food and Drug Administration issued Emergency Use Authorization (EUA) for use of Hydroxychloroquine Sulfate for treatment of 2019 Coronavirus disease. However, on July 4, 2020, the World Health Organization announced that it would stop the hydroxychloroquine trial on the grounds because “the mortality rate of hospitalized patients with coronary disease could not be relieved during the trial”. In August 2020, the “Covid-19 Diagnosis and Treatment Plan (Trial Eighth Edition)” issued by the National Health Commission of China stated that “hydroxychloroquine or combined use with azithromycin is not recommended.”

The sales volume increased in the short term when used in the experimental prevention and treatment at the beginning of 2020. It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.
Topics Covered:
-The impact of COVID-19 on China’s hydroxychloroquine market
-Market size of hydroxychloroquine in China
-Major R hydroxychloroquine manufacturers in China
-Prices of hydroxychloroquine in China
-Major factors affecting the development of China’s hydroxychloroquine market
-Prospect of China’s hydroxychloroquine market

The post Investigation Report on China’s Hydroxychloroquine Market, 2021-2025 first appeared on CRI Report.

Topics Covered:
-The impact of COVID-19 on China’s insulin lispro market
-Situation of diabetes and overview of the antidiabetic drug market in China
-Market size of Recombinant Lispro Insulin in China
-Major Recombinant Lispro Insulin manufacturers in China
-Prices of Recombinant Lispro Insulin in China
-Major factors affecting the development of China’s Recombinant Lispro Insulin market
-Prospect of China’s Recombinant Lispro Insulin market

The post Investigation Report on China’s Recombinant Lispro Insulin Market, 2021-2025 first appeared on CRI Report.